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Abstract: A literature review was conducted to identify evidence of cases and outbreaks of
vaccine-preventable diseases (VPDs) that have been reported from on board ships and the methods
applied on board for prevention and control, worldwide, in 1990 to April 2019. Moreover, evidence
from seroprevalence studies for the same diseases were also included. The literature review was
conducted according to Preferred Reporting Items for Systematic reviews (PRISMA) guidelines.
A total of 1795 cases (115 outbreaks, 7 case reports) were identified, the majority were among
crew (1466/1795, 81.7%) and were varicella cases (1497, 83.4%). The origin of crew cases was from
sub-tropical countries in many reports. Measles (40 cases, 69% among crew), rubella (47, 88.7%),
herpes zoster (9, 69.2%) and varicella cases (1316, 87.9%) were more frequent among crew. Mumps
cases were equal among passengers and crew (22/22). Hepatitis A (73/92, 70.3%), meningococcal
meningitis (16/29, 44.8%), and pertussis (9/9) were more frequent among passengers. Two outbreaks
resulted in 262 secondary measles cases on land. Review results were used to draft a new chapter for
prevention and control of VPDs in the European Manual for Hygiene Standards and Communicable
Disease Surveillance on Passenger Ships. Despite past and current evidence for cross-border VPD
transmission and maritime occupational risks, documented pre-employment examination of immune
status, vaccination of seafarers, and travel advice to passengers are not yet regulated.
Keywords: vaccine; cruise; ship; travel; maritime health; varicella; chickenpox; mumps; rubella;
measles; pertussis; diphtheria; meningococcal disease; hepatitis A; vaccination; occupational health;
seafarers; sailors
1. Introduction
Ships are long acknowledged as semi-closed and densely populated environments with close living
and sleeping quarters, and shared water, ventilation and sewage systems [1–3]. Such environments
are accountable to a constant flux of people from over the world and conducive for the spread of
communicable diseases.
Approximately 397 million passengers embarked and disembarked in European Union (EU) ports
in 2016 [4]. It was estimated that 26.6 million tourists spent holidays on cruise ships worldwide in
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2017 [5], while a total of 1,647,500 seafarers work on merchant ships operating internationally over
the world [6]. The risk of cases and outbreaks of disease among the population on board ships is
ever present.
Outbreaks of norovirus and influenza, as well as food and waterborne disease, are well
documented [7–10]. In recent years, outbreaks of diseases, which could be prevented by routine vaccines
(e.g., measles, rubella, and varicella) have also been reported on ships [11,12]. This is not surprising
as both crew and passengers originate from diverse countries with variable vaccine schedules and
coverage. However, even in countries where measles was declared eliminated, land-based community
outbreaks are currently ongoing [13]. In response to these events, governments and international
agencies have developed national [14] and international guidelines [15,16] to provide advice for timely
prevention and control.
In light of events constituting cross-border health threats under the legal framework of the
International Health Regulations (2005) and the Decision no 1082/2013/EU on serious cross-border
threats to health, updated European guidance was also requested by EU Member States [17,18].
As such, the EU SHIPSAN ACT joint action [19] chose to update the “European Manual for Hygiene
Standards and Communicable Disease Surveillance on Passenger Ships” to include a chapter on
vaccine-preventable diseases (VPDs) [16]. In writing up-to-date guidelines on VPDs, the evidence-base
for the occurrence of disease and characteristics of outbreaks or other events that could be prevented by
routine vaccination, on ships, and the methods applied for their prevention and control, was reviewed.
To our knowledge there has been no other review published with this objective.
2. Materials and Methods
2.1. Research Question and Objectives
The bibliographic review was conducted in order to answer the following research questions:
1. What is the published evidence of cases and outbreaks of measles, mumps, rubella, varicella,
diphtheria, tetanus, pertussis, meningococcal disease, hepatitis A, and hepatitis B that have been
reported from on board ships and the methods applied on board for the prevention and control,
worldwide, since 1990?
2. What is the published evidence of exposure of travelers to measles, mumps, rubella, varicella,
diphtheria, tetanus, pertussis, meningococcal disease, hepatitis A, and hepatitis B, based on
serological examinations, worldwide, since 1990?
This review aims at giving an insight on VPDs on board ships that have occurred worldwide, by
analyzing evidence published since 1990. Results of this review were used in the revision of the “European
Manual for Hygiene Standards and Communicable Disease Surveillance on Passenger Ships” [16].
The specific objectives of the review were the following:
• To undertake descriptive epidemiology (person, place and time characteristics) of cases
and outbreaks of VPDs (measles, mumps, rubella, varicella, diphtheria, tetanus, pertussis,
meningococcal disease, hepatitis A, and hepatitis B) that have been reported from on board ships
since 1990.
• To describe the cause/risk factors identified for introduction and transmission of these VPDs
onto ships.
• To describe key methods applied for the prevention and control of these VPDs on ships.
2.2. Search Strategy
The search concepts used for the above-mentioned topic are: (a) Public health event: Cases or
outbreaks, or evidence for exposure based on serological examinations to VPDs including measles,
mumps, rubella, varicella, herpes zoster, diphtheria, tetanus, pertussis, meningococcal disease, hepatitis
Int. J. Environ. Res. Public Health 2019, 16, 2713 3 of 21
A, and hepatitis B; (b) type of intervention: Prevention and control measures of those VPD; (c) population
of interest: Humans travelling with ships; (d) setting: Ships; (e) outcome: Effectiveness of measures
applied, cost, public health impact.
The systematic review was performed according to the procedures and checklist outlined by the
Preferred Reporting Items for Systematic reviews (PRISMA) [20]. To retrieve information, Pubmed
was searched for relevant articles published between 1 January 1990 and 30 April 2019 in English,
German or Greek. Moreover, the German Institute of Medical Documentation and Information (DIMDI)
databases (includes Medline, Embase, Embase Alert, Biosis Previews, SciSearch) were searched for
relevant articles published between 1 January 1990 and 15 July 2015 in any of the official EU languages.
All text fields were searched using the following search terms:
(ship OR ferry* OR boat* OR yacht* OR cruise* OR barge* OR “fishing vessel” OR tanker* OR
“on board” OR aboard OR “maritime transport”) AND (chickenpox OR diphtheria OR “German
measles” OR hepatitis A OR hepatitis B OR measles OR “meningococcal disease” OR meningitis OR
mumps OR pertussis OR rubella OR tetanus OR varicella). An asterix was used for abridged terms.
Within articles selected for full-text analysis, the reference lists were checked for completeness.
The SHIPSAN TRAINET communication platform was searched for relevant vaccine-preventable
disease cases or outbreaks between 29 March of 2011 (establishment of platform) and 30 April 2019 [21].
Furthermore, the World Health Organization, the European Centre for Disease Prevention and Control
(ECDC) and the United States Centers for Disease Control and Prevention (US-CDC) Division of Global
Migration and Quarantine (DGMQ) were contacted separately for surveillance or outbreak reports
relating to VPDs outbreaks on ships.
2.3. Inclusion and Exclusion Criteria
Inclusion criteria were: Articles or reports or record reviews or other documents published
in peer-reviewed journals or national and international organizations’ publications or information
through personal communications, from January 1990 until April 2019, that reported any seroprevalence
evidence or clinically and/or laboratory confirmed case or outbreak of measles, mumps, rubella, varicella,
diphtheria, tetanus, pertussis, meningococcal disease, hepatitis A, and hepatitis B, on board ships
sailing worldwide.
Exclusion criteria were: Publications reporting influenza were excluded from the review since there
was existing recommended policy in the “European Manual for Hygiene Standards and Communicable
Disease Surveillance on Passenger Ships” [16]. Moreover, those VPDs where there was not considered
a risk specifically related to ships (e.g., Japanese encephalitis, rabies) and for risk groups based on
age, occupation, underlying health condition, etc. (e.g., pneumococcal disease, rotavirus) were also
excluded. Articles for which the full text was not available in English or German or Greek were also
excluded. Moreover, full-text reports/articles were excluded if: no cases of VPDs reported (including
review articles with no original data), data outside time range, different versions of same report/article,
reports from hospital ships, or ships used to house displaced populations/refugees.
2.4. Data Extraction and Analysis
The quality of articles included in the review were assessed on the basis of completing the
inclusion criteria. Specific questions and a data extraction sheet were used by the two researchers
to independently and systematically review and extract the data from the publications. The data
extraction sheet was pilot-tested on records/articles and then refined accordingly.
Duplicates and reports including data from prior to 1990 were excluded (Figure 1). Only references
for which full text could be obtained and; therefore, analysis performed were included. For events
with multiple reports, the original report was included and additional reports were only included if
they contained additional information relevant for data extraction. For all included articles, full-text
analysis was performed.
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We contacted authors from one paper for further information: Nieto Vera et al. Measles outbreak
in Campo de Gibraltar, Cadiz, Spain, during the period February–July 2008 [22]. The number of
laboratory-confirmed, epidemiologically-linked, and clinically compatible cases was clarified. As was
the onset date of the last case and the number of hospitalizations.
2.5. Ethical Approval
This review concerns a review of already published material, and; therefore, ethical approval
was not required. Moreover, data extracted from the EU SHIPSAN information system (https:
//sis.shipsan.eu/) owned by the EU SHIPSAN ACT partnership who approved the use of data for the
systematic review and had the tasks to conduct this literature review and to revise the “European
Manual for Hygiene Standards and Communicable Disease Surveillance on Passenger Ships” in the
framework of the EU SHIPSAN ACT joint action [16].
3. Results
3.1. Reports Included in the Review
Twenty-six articles/reports fulfilled the eligibility criteria (Figure 1). Additionally, eight records in
the EU SHIPSAN ACT joint action information system and one personal communication reported
cases or outbreaks of VPDs associated with ships were included in this review (Figure 1) [21,23]. The
systematic review revealed 24 events including 17 outbreaks and seven single case events, which
occurred between 1 January 1990 and 30 April 2019 on passenger, cargo, military, and work ships
(Tables 1–3). Moreover, the systematic review analyzed data from five studies that presented results
from review of ships’ or of authorities’ records and four studies reporting serological test results
of seafarers.Int. J. Environ. Res. Public Health 2019, 16, x 5 of 20 
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In total, 1795 cases (115 outbreaks, seven case reports) were identified, the majority were among
crew (1466/1795, 81.7%) and were varicella cases (1497, 83.4%). The origin of crew cases was from
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sub-tropical countries in many reports. Measles (40 cases, 69% among crew), rubella (47, 88.7% crew),
herpes zoster (9, 69.2% crew), and varicella cases (1316, 87.9% crew) were more frequent among
crew. Mumps cases were equal among passengers and crew (22/22). Hepatitis A (73/92, 70.3%),
meningococcal meningitis (16/29, 44.8%), and pertussis (9/9) were more frequent among passengers.
3.2. Single Case Reports
There were single case reports of each of diphtheria (in 1997), hepatitis A (in 2011), meningococcal
meningitis case (in 2017), and varicella (in 2014 and 2018) from passenger ships, a meningococcal meningitis
case from a military ship (in 2003) and varicella (in 2015) from cargo ships (Table 1) [21,24–27]. Six of the
seven case reports were in crew with the exception being the diphtheria case, which was in a passenger [24].
Except from one death reported due to varicella [25], there were no other deaths reported. The case of
meningitis (in 2017) and the diphtheria case were the only cases reported to be hospitalized ashore [21,24].
Regarding source of infection for the diphtheria case reported in a passenger, characterization
of the diphtheria isolate found that the strain was indistinguishable from the predominant epidemic
strain that was currently circulating in the countries of the former Union of Soviet Socialist Republics,
providing evidence that the infection was likely acquired during the Baltic cruise [24].
Response measures were described in six out of the seven reports. In the three cases of varicella,
isolation, case finding/active surveillance in crew and crew vaccination were applied and cases were
reported to authorities [21,25]. Treatment, cleaning/disinfection and risk communication were described
to be applied in response to one varicella case [21]. In response to the diphtheria case, diphtheria
antitoxin and antibiotics were given to each case and close family, while contacts received antibiotic
prophylaxis and low dose diphtheria vaccine boosters. Meningitis cases were isolated, in one case
chemoprophylaxis was given to close contacts from the ship and contact tracing conducted [21,26].
3.3. Outbreaks Reported (Events with More Than One Case Involved)
3.3.1. Characteristics of Outbreak Setting and Affected Population
The review revealed 17 outbreaks of VPDs that have occurred world-wide based on the reports
that fulfilled the eligibility criteria, between 1996 and 2019. Those outbreaks were varicella (n = 5),
measles (n = 3), rubella (n = 3), a multi-pathogen varicella–measles–rubella outbreak (n = 1), hepatitis
A (n = 3), meningitis (n = 1), and mumps (n = 1). Outbreaks were associated with passenger ships
(13 cruise ships and one ferry), military (navy) ships (n = 2), and a cargo ship (n = 1) sailing world-wide
(Table 1). Most cases were reported on ships associated with hepatitis A, varicella, rubella, and measles
outbreaks, with 71, 63, 43, and 37 cases, respectively (Table 4). Two articles reported 262 secondary
measles cases on land [22,28].
The duration of the majority of the outbreaks (n = 13) were protracted (over one month long)
(Table 1) with the longest duration being for a varicella outbreak that spread between crew members
of different ships (10 months) [23] and a measles outbreak that spread onto land (six months) [22,28].
Only one death was reported, during the meningitis 2012 outbreak (case fatality rate 25%) [29].
Hospitalizations were reported in seven outbreaks (7/17, 41%) and the hospitalization rate varied
between 8% to 100%, being highest in the meningitis 2012 (n = 4/4, 100%) and hepatitis A (n = 20/34,
59%) outbreaks (Table 1) [29,30].
The majority of outbreaks involved crew members (14/17, 82%). Eleven outbreaks (11/17, 65%)
affected only crew members and in two further measles outbreaks [22,28,31], crew were identified as
the index cases leading to secondary crew cases, cases in passengers, and those on land [22,28]. One
varicella outbreak in 2012 affected both crew and passengers and the index case was not reported [21].
In the three outbreaks of hepatitis A, all cases were reported in passengers on Nile cruises.
The total number of crew affected in outbreaks (n = 145) were almost double the number of passengers
cases (n = 78) (Table 4). Crew attack rates, calculated using total crew as the denominator, ranged from
<1% to 6% (Table 1). It should be noted that the two highest attack rates (4% and 6%) were derived from
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sero-surveys after confirmed rubella outbreaks, which included asymptomatic cases (approx. 50% of
cases in both studies); the highest attack (6%) was for a rubella outbreak on a Navy ship where no control
measures were documented and the outbreak only ended after the ship’s return [3]. The mumps outbreak
had a crew attack rate of 4%, and a crew attack rate of 2.4% was calculated from the data available for the
measles outbreak in 2014 [31]. Insufficient data were available for most varicella outbreaks to calculate the
attack rate, but in two outbreaks it was less than 1% of crew (Table 1) [1,32]. In those outbreaks and events,
which documented the nationality of crew from passenger ships (n = 10) (Table 1), all noted crew from a
range of countries (some ships had crew from over 130 countries), including a substantial proportion of
crew originating from sub-tropical/tropical countries (Table 4). Insufficient data were reported to describe
attack rates, the risk of secondary transmission to, or nationality of affected passengers.
3.3.2. Secondary Cases on Land
Two measles outbreaks linked to passenger ships are of particular interest as they reported a
large number of cases and exemplify the risk of transmission of VPDs among crew, passengers and
to others on land [22,28]. A measles outbreak in 2014, which started on a cruise ship in the western
Mediterranean in 2014 [31], and another related to a fast ferry operating on the Algeciras (Spain)-Tangier
(Morocco) route in 2008 [22], both led to extended outbreaks involving a substantial number of cases
on land in Italy (n = 110) [28,31] and Spain (n = 152), respectively [22]. For the ferry outbreak in 2008,
there were three index cases, two of which were crew members, which disembarked the ferry and led
to a large outbreak in the county of Campo de Gibraltar in Spain [22]. In total 155 cases of measles were
reported in the county over six months between February and July 2008, of which 88% (n = 137) were
laboratory confirmed. An incidence rate of 112.3 cases of measles per 105 population was reported in
the Province of Algeciras which experienced most (83%) of the cases.
For the 2014 measles outbreak on a cruise ship, as of 10 March 2014, there were 29 laboratory
confirmed cases, 80% (n = 23) of the cases were crew [3,31]. Twenty-three of the 968 crew (2.4%) and
six of approximately 3352 passengers (0.2%) became infected with measles over a three-week period.
In addition to sporadic contacts of primary cases becoming infected, two secondary outbreaks linked
to passenger cases and involving extensive nosocomial transmission were reported on land [22,28].
One secondary outbreak occurred in Brindisi province, Puglia Region and involved 32 cases to 8 May
2014 [33]. The outbreak was spread within an emergency department of a hospital (including two
health care worker cases) and then in the community to the fifth generation. The other secondary
outbreak was even more extensive and led to 80 cases to July 2014 in Sardinia with transmission in
families, work places and the hospital setting [28]. Nosocomial cases included health care workers
(n = 15, 19%) and patients infected while in the emergency department or hospital ward (n = 29, 36%).
In total, 45% (35/78) case-patients were hospitalized. In all these secondary outbreaks, most cases were
young adults, but children including those <2 years old were also affected (Table 1).
3.3.3. Vaccination History of Travelers
Half of the outbreaks involving crew (7/14, 50%) documented the vaccination history or
susceptibility rate of crew members and all found insufficient vaccination and/or documentation
(Table 1). In all three rubella outbreaks, a substantial proportion of crew were found to have negative or
no documentation of rubella vaccination or immunity (75%, 81%, and 96%, respectively) [3,34]. In the
measles 2014 outbreak, 85% of all crew and 21/24 cases (87.5%) had a negative or unknown vaccination
history [28]. In the measles 2008 outbreak, 72% of cases had not been previously vaccinated [22]. In the
mixed rash 2006 outbreak, only three crew members (<1%) had proof of immunity (a vaccine record)
to measles or rubella [1]. Three of nine (33%) mumps cases had a mumps or measles–mumps–rubella
(MMR) vaccine documented in the mumps 1992 outbreak [35]. For the three hepatitis A outbreaks
involving only passengers, all reports documented that none of the cases had been vaccinated against
hepatitis A [30,36,37].
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3.3.4. Source of Outbreaks
Although most reports could determine the index case or cases of outbreaks, little data exists on
the source of outbreaks or risk factors for transmission. The source of the three likely inter-linked
hepatitis A outbreaks affecting only passengers was hypothesized to be a continuing common source
linked to Nile river cruises [30,36,37].
For the 12 outbreaks for which a crew member(s) was identified as the index case, only four
outbreak reports discussed the likely exposure/source and believed the source of the outbreaks to have
been exposure of crew on land, either before deployment or at one of the stops (Table 1).
In the rubella 1996 outbreak, three primary crew cases, all Germans, were thought to be infected
off-ship and pre-deployment, as there became sick 8 to 10 days into deployment (within the incubation
period), it could not be determined if the cases had the same source [3]. Sleeping in the ratings deck
(basic rank, slept 40–80 per dorm and shared air-conditioning) was determined to be a risk factor for
becoming infected with rubella in this outbreak, with sleeping conditions likely favoring transmission.
In the measles 2014 outbreak, a common exposure on board could not be found and the index
crew member (origin not stated; 71% of crew from Asia) was thought likely infected at one of stops [31]
or on board [28].
In the mixed rash outbreak in 2006, it was concluded that rubella was imported from the Philippines
(Filipino crew member boarded nine days prior to onset), measles from the Ukraine (Ukrainian crew
member boarded 13 days prior to onset) and varicella from unknown source country (possibly one of
the ship stops as crew members boarded 22 days prior to onset) [1]. The authors also commented that
close crew interactions outside the work environment played a role in the spread of the outbreak as
there was sustained varicella transmission among crew members with different occupations.
In the meningitis 2012 outbreak, all cases were working in the ship’s kitchen and originated from
different countries in three different continents [29].
In two reports involving rubella, the potential risk of congenital rubella syndrome for passengers
or crew of childbearing age was estimated. In one report, 33% of passenger responders were of
childbearing age and 0.8% were pregnant [34]. In the other report, three crew members and 0.8% of
passengers were pregnant [1].
3.3.5. Response Measures
All outbreak reports included reference to at least one response measure being used to control the
outbreak (Table 1). In over half of the outbreaks, a report was sent to competent authorities (11/17,
65%) and isolation (10/17, 59%) were applied. Active surveillance or case finding in crew (8/17, 47%),
risk communication with crew and/or passengers (8/17, 47%), and treatment of cases (7/17, 41%) were
also commonly cited. Contact tracing (4/17, 23.5%), case finding/active surveillance in passengers or
others (5/17, 29%), and cleaning/disinfection (4/17, 23.5%) were less frequently cited control measures.
Only in one outbreak (measles 2014) was quarantine implemented and in two outbreaks (measles
2014 and mumps 1992) was disembarkation applied (Table 1) [3,31,35]. Vaccination was described
as a post-prophylactic measure for crew in ten measles, varicella, and/or rubella outbreaks; and
for passengers in two measles outbreaks. The number of vaccines administered were cited in four
outbreaks: a total of 127/1020 (12.5%) crew received vaccine in the measles 2011 outbreak which
involved five crew cases [23], more than 400 crew on five different ships (total number of crew not
stated) in the varicella 2008 outbreak that included 28 crew cases [23], 865/900 (96%) crew in the rubella
April to June 1997 outbreak with seven crew cases [34], and 1191/1200 (99%) crew in the mixed rash
outbreak 2006 with 16 crew cases [1]. No outbreak report described the use of immunoglobulin for
post-exposure prophylaxis in either crew or passengers. However, it was described as used in close
contacts on land in the extended measles outbreak in 2008 [22]. Costs of control measures to interrupt
transmission were only cited in the mixed rash outbreak in 2006 that involved 16 crew cases on a
passenger ship and was estimated at 67,000 USD for vaccinations, supplies, and health department
staff time [1]. Specific guidelines were not cited as being applied or being recommended apart for in
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the measles 2014 outbreak, where in the absence of contact tracing guidelines specifically for ships, the
Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft (RAGIDA) guidelines for
aircraft were recommend to be adapted [28].
3.4. Events of VPDs Identified through Record Review Studies
Record reviews identified a total of 1572 cases (1321 crew and 251 passengers). The four record
reviews of surveillance data were undertaken between 2005 and 2015, for periods of six months, two
years, and five years, the latter being for two reviews (Table 4). One review was of cruise ship medical
logbooks from 34 cruise ships sailing into north America, 2009–2010 [38], one of cruise and cargo ship
reports to Hamburg Port Health, Germany from world-wide cruises, November 2007 to April 2008 [39]
and two of the US Centers for Disease Control and Prevention national database of cruise ships sailing
in US waters, 2005–2009 [40,41].
These record reviews also found that the majority of cases reported were crew (78–100% of cases);
one US study found that only crew were responsible for being the index cases of outbreaks of varicella [38].
However, passenger cases and their contacts were reported in addition to crew members in two reviews
(36 and 79 cases, respectively) (Table 4). Both US studies also found that a substantial proportion of
varicella cases are associated with outbreaks on-board: One review found that 70% of crew cases (n = 66)
were accountable to 18 clusters/outbreaks (defined as two or more epi-linked cases, two to nine cases per
outbreak) and the other review found that 47.6% of crew and passenger cases (n = 89) were accountable to
eight outbreaks (defined as five or more epi-linked cases, six to 26 cases per outbreak) [38,40].
The first study found that the majority of cases were first-generation (68%); however, there were
also second and third-generation cases reported [40]. Two varicella record reviews recorded the age
and sex of infected crew and found the majority to be male (100% and 80%, respectively) and the age
range was 26–42 years [39] and 20–66 years (median 29 years) [40], respectively.
Only the German record review conducted in four ships addressed the possible source of the
cases and identified non-immune employers as having been infected from an infected child (n = 1) or
other crew members on board (n = 3) [39]. The US studies described control measures in-line with the
published US-CDC Guidance’ Guidance for Cruise Ships on Varicella (Chickenpox) Management’ [14]
and the German study in-line with the Port Health Centre recommendations (listed in the paper,
no guideline referenced). Both recommendations included isolation of cases and contact tracing to
allow for contact (post-exposure) vaccination. According to the authors, such recommendations were
followed and were useful in controlling the outbreaks.
Records of reported deaths in the US revealed five deaths due to meningitis/meningococcal
disease, three of them were among passengers [11].
3.5. Evidence of VPDs Based on Serological Tests on Seafarers
Three seroprevalence studies were undertaken in ships’ crew for hepatitis A, B, and C in the
1990s and one for varicella in 2008 (Table 3). In addition, two of the rubella outbreak reports [3,34]
and one varicella outbreak report [32] included seroprevalence studies. These studies found that 11%
of cruise ship crew and 12% of navy ship crew were acutely infected or susceptible to rubella; and
13% [32] and 16.5% [42] of crew were susceptible to varicella in two different studies, respectively.
For the varicella outbreak it was estimated that “the ship population was two to three times more
susceptible to varicella than an age-comparable US population” [32]. Hepatitis A susceptibility of ship
crew was found to be between 85% to 100% and was positively associated with age in two studies
(Table 3) [43–45]. Anti-hepatitis A virus (HAV) and anti-hepatitis B virus (HBV) positivity was found
associated with those who had international deployment [43,44].
In the varicella 2008 study, the cost of antibody testing and vaccination was 7000 USD and the
paper concludes that testing for antibodies followed by vaccination is a cost-effective method to
prevent outbreaks on cruise ships and a recommended mandatory part of the pre-employment medical
examination for Indian seafarers [42].
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Table 1. Descriptive analysis of outbreak and case reports of vaccine-preventable diseases.
Disease
Dates, Number of
Affected Voyages
(Duration)
Diagnosis/Case
Definition
No. Cases
(Crew, Pax,
Other)
Age, Sex, Nationality of
Cases
No.
Hospitalizations
(HR),
No. Deaths
Crew Attack
Rate
(of Susceptible)
Place of Occurrence/
Ship Type Vaccination/Infection History
Source/Risk
Factor
Control Measures
Described * Reference
Rubella
2 May–28 June 1996,
1 (2 months)
Rubella IgM+ or
IgG+ plus clinical
exanthema
20 (20, 0, 0)
18–33 years (mean 22.6);
all male,
German
0 (0%), 0 6% crew (57%)
Unkn. ‡.
(ashore)/Military
(German Navy ship)
A total of 9% (n = 27) had
documentation of vaccination
status, 81% (n = 242) had not
been vaccinated or did not know
status, 36% (n = 98) of crew
indicated they had rubella in the
past—of which three became
cases; Susceptibility rate: 12%
(35/292) including infected
Crew;
Hypothesized
source: off ship
pre-employment/
Highest risk of
infection: sleeping
aboard ratings
deck
A, C, E [3]
April–June 1997,
multiple (3 months) Rash illness 7 (7, 0, 0)
Unkn., unkn.
95% not US-born 0 (0%), 0
0.8% crew
(unkn)
Florida (USA) to
Bahamas/Passenger
(cruise)
Substantial proportion (96%,
n = 865) of crew had no
documentation of rubella
vaccination or immunity
Unkn. B, I [34]
30 May–2 August
1997, multiple
(2 months)
Rubella IgM+ or
clinical Rubella
plus epi-link to
confirmed case
16 (16, 0, 0)
Unkn., unkn.
85% not US born from 50
countries
0 (0%), 0 4.2% crew (64%)
Florida (USA) to
Bahamas/Passenger
(cruise)
75% of crew had negative or
unknown vaccination history,
Susceptibility rate: 11%
(41//366) including infected
Unkn. B, E, F, G, I [34]
Measles
2 February–18 July
2008, N/A
(6 months)
Confirmed or
epi-linked clinical
measles
155 (2, 1, 152)
Age range: 5 months-41
years (38% 20–29 years: 19%
<2 years); 54% male, unkn.
13 (8,4%),0 N/A
Algeciras
(Spain)—Tanger
(Morocco)/Passenger
(ferry) and Land
(Algeciras and
surrounds)
72.1% of cases not previously
vaccinated
Index cases were 2
crew and 1
passenger
A, F, G, N
(vaccination and Ig
to susceptible
contacts)
[22]
19–26 Aug 2011,
Various (8 days)
Confirmed
measles 5 (5, 0, 0)
Unkn., 4 male, 1 female,
Philippines: 3, Honduras: 1,
Italy: 1
0 (0%), 0 0.5% (unkn.) Spain, Malta,Italy/Passenger Unkn. Unkn.
A, B, C, D, E, F, G,
H, I, J [21]
8 February–July
2014, N/A (6
months)
Epi-linked and
confirmed 80 (0, 1, 79)
Median age 26 years (range:
8 months–55 years); 50
(62.5%) female, N/A
35/78 (44.9%), 0 Unkn. Sardinia, Italy/Land
74/76 cases (97.4%) unvaccinated:
2 (2.6%) with one dose of
measles vaccine
Cruise ship
passenger
H, G, N (all
susceptible staff
invited for
vaccination)
[28]
20 February–10
March 2014,
1 (7 days)
Clinical, epi-
linked and
confirmed
29 (23, 6, 0)
1–42 years (median 26); 21/27
(78%) male, Asia (71%),
Europe (21%), S. America
and Caribbean (7%), Africa
(0.5%) Median age 19 years
(range: 0–39 years); 17 (53%)
female,
Italy: 6, India: 5, Philippines:
3, Honduras: 2, Austria: 1,
Brazil: 1, Indonesia: 1
10/27 (37%), 0 2.4% (unkn.)
Mediterranean Sea
(Italy, France,
Spain)/Passenger
(cruise)
Vaccination status of 24 cases:
unkn. (n = 12), unvaccinated
(n = 9), vaccinated with one to
two doses (n = 2, n = 1). Of crew,
142 recalled vaccination and
108 history of measles = 150/968
Index case: crew
member(s):
infected during
cruise, possibly at
one of stops
A, B, E, F, G, H, I, J,
K, O [3,31]
27 February–May
2014, N/A
(3 months)
Clinical, epi-
linked and
confirmed
32 (0, 1, 31) Unkn. Unkn. Unkn.
Brindisi province,
Puglia Region,
Italy/Land
Unknown; 1/32 cases vaccinated
with one dose of MMR
Cruise ship
passenger
H, N (MMR
vaccination for
2 cases on land as
PEP and of
close contacts)
[33]
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Table 1. Cont.
Disease
Dates, Number of
Affected Voyages
(Duration)
Diagnosis/Case
Definition
No. Cases
(Crew, Pax,
Other)
Age, Sex, Nationality of
Cases
No.
Hospitalizations
(HR),
No. Deaths
Crew Attack
Rate
(of Susceptible)
Place of Occurrence/
Ship Type Vaccination/Infection History
Source/Risk
Factor
Control Measures
Described * Reference
Varicella
1998, unkn. (unkn.) Clinical varicellacase 3 (3, 0, 0)
Unkn.,
Most foreign-borne, many
from tropical climates
Unkn. <1% (unkn.)
New York
Harbor/Passenger
(cruise)
Susceptibility rate including
infected 13%. Unkn. A, C, I [32]
28 January–15 April
2006 Multiple
(7 days), (11 weeks)
Rash illness 16 (16, 0, 0)
Index cases 23 and 35 years,
unkn., Ukraine and
Philippines.
Secondary cases: unkn.,
unkn., majority from tropical
countries.
0 (0%), 0 1.3% (unkn.)
Florida (US) to
Caribbean./Passenger
(cruise)
Three crew members (<1%) had
proof of immunity (vaccine
record) to measles and rubella
All index cases
were crew
members; close
crew interactions
outside of work as
risk factor
A, B, E, F, G, H, I [1]
February–November
2008 5 ships (unkn.),
(10 months)
Clinical varicella
case 28 (28, 0, 0)
Unkn.,
70% crew from
subtropical/tropical countries
0 (0%), 0 Unkn. MediterraneanSea/Passenger Unkn. Unkn. I [23]
20 February–30
March 2012, 1
(5 weeks)
Clinical varicella
case 3 (2, 1, 0) 4 years, male, unkn. 0 (0%), 0 <1% (unkn.)
UK, Spain,
Portugal/Passenger Unkn. Unkn. A, B, C, D, E, G, I [21]
29 September–2
October 2014,
1 (4 days)
Clinical varicella
case 1 (1, 0, 0) 27 years, male, unkn. 0 (0%), 0 Unkn.
Malta,
Spain/Passenger Unkn. Unkn. A, B, C, D, E, G, I [21]
16 January–20
February 2015
Various (5 weeks)
Clinical varicella
case 5 (5, 0, 0)
34 years, male, unkn.,
Indonesia 0 (0%), 0 Unkn.
Spain,
Italy/Passenger Unkn. Unkn. A, B, C, D, E, G, I [21]
26–30 December
2015, N/A (1 week)
Varicella
pneumonia 1 (1, 0, 0) 50 years, male, Indian
1/1 (100%), 1
(cause of death
varicella
pneumonia)
1/24 (unkn.) Puerto Rico/Cargo Unkn. Unkn. A, B, E, I [25]
12–21 September
2016 5 (5, 0, 0) Unkn. 0 (0%), 0 Unkn. Belgium/Cargo ship Unkn.
New crew
members from the
Philippines
arrived
(22/08/2016) prior
to the outbreak or
by contacting
people in the port
A, B, C, E, I [21]
February 2018, 1
Clinically
diagnosed
varicella
1 (1, 0, 0) Unkn., male, Philippines 0 (0%), 0 Unkn. Spain/Container ship Unkn. Unkn. A, B, I, E [21]
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Table 1. Cont.
Disease
Dates, Number of
Affected Voyages
(Duration)
Diagnosis/Case
Definition
No. Cases
(Crew, Pax,
Other)
Age, Sex, Nationality of
Cases
No.
Hospitalizations
(HR),
No. Deaths
Crew Attack
Rate
(of Susceptible)
Place of Occurrence/
Ship Type Vaccination/Infection History
Source/Risk
Factor
Control Measures
Described * Reference
Hepatitis
A
1 September–30
November/2008, 3
(3 months)
Clinically
compatible case
with IgM
anti-HAV, disease
onset 1 Sept–30
Nov and travel
history to Egypt
2–6 weeks prior to
symptom onset
10 (0, 10, 0)
Median 41 years (range
23–59); male to female ratio
3:7, N/A
1 (10%), 0 Unkn.
Nile river,
Belgium/Passenger
(river cruise
No case vaccinated against
hepatitis A
Continuing
common source,
most likely linked
to river cruise
B [37]
September–November
2008, 6 (5–14 days),
(10 weeks)
Hepatitis A cases
(symptoms + lab
confirmation of
acute infection)
with onset from 1
Sept 2008 and
travel to Egypt
15–50 days prior to
symptom onset
34 (0, 34, 0) Mean age 40.1 years (range11–69); 59% female, N/A 20 (59%), 0 Unkn.
Nile river,
Germany/Passenger
(river cruise
No case vaccinated against
hepatitis A
Continuing
common source,
most likely linked
to river cruise
B [30]
13 September–28
October 2009, 5
(9 weeks)
Person with IgM
anti-HAV who had
stayed in Egypt
2–6 weeks prior to
symptom onset
26 (0, 26, 0) Mean age 32.8 years (range10–65); 50% female, N/A 17 (65%), 0 Unkn.
Nile river,
France/Passenger
(river cruise
No case vaccinated against
hepatitis A
Continuing
common source,
most likely linked
to river cruise
B [36]
January 2011, 1
(unkn.)
Subgenotype IB
imported case 1 (1, 0, 0) 28 years, male, Polish 0, 0 Unkn.
Argentina
(USA–South
American
Pacific–Atlantic
Coast)/Passenger
(river cruise
Self-report of one dose hepatitis
A vaccine in previous year
Crew index case;
Possible risk factor:
consumption of
shellfish on land in
Mexico
O [27]
Mumps
15 June–13 August
1992, 1 (unkn.)
(2 months)
Clinical mumps 9 (9, 0, 0) Mean 24 years (Range:18–35); unkn., unkn. 2 (22%), 0 4% (unkn.)
Western Pacific,
route: Japan to
Hawaii (US)/Military
(“US Reuben James”
Navy ship)
Three cases had mumps or MMR
vaccine documented Unkn. O [35]
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Table 1. Cont.
Disease
Dates, Number of
Affected Voyages
(Duration)
Diagnosis/Case
Definition
No. Cases
(Crew, Pax,
Other)
Age, Sex, Nationality of
Cases
No.
Hospitalizations
(HR),
No. Deaths
Crew Attack
Rate
(of Susceptible)
Place of Occurrence/
Ship Type Vaccination/Infection History
Source/Risk
Factor
Control Measures
Described * Reference
Diphtheria 1997,1 (12 days)
Confirmed
Corynebacterium
diphtheriae
1 (0, 1, 0) 72 years, female, unkn. 1 (100%), 0 N/A Baltic sea/Passenger(cruise) Unkn.
Travelling in
former
USSR/Baltic
C, N (Diptheria
antitoxin and
antibiotics to case
and close family,
contacts received
antibiotic
prophylaxis and
low dose
diphtheria vaccine
boosters)
[24]
Meningitis
May 2003,
1 (unkn.)
Clinical
meningococcal
meningitis
1 (1, 0, 0) 24 years, male, unkn. 0, 0 Unkn.
Mid Atlantic
ocean/Military
(aircraft carrier)
Patient had received
meningococcal vaccine three
years previously.
Unkn.
A, C, H, N
(Chemoprophylaxis
to close contacts
from the ship)
[26]
October 2012, 1
(unkn.), (<1 month)
Confirmed
Neisseria
meningitides
4 (4, 0, 0)
Unkn., unkn., originated
from three different
continents
4 (100%), 1
(25%) Unkn.
Italian
coast/Passenger
(cruise)
Unkn. All cases workedin ship kitchen
B, N
(Chemoprophylaxis
to all passengers
and crew on ship)
[29]
October 2017, 1 Clinical meningitis 1 (1, 0, 0) Unkn., female, unkn. 1, unkn. Unkn. Greece/Passenger(cruise) Unkn. Unkn. A, B, D, I, O [21]
HR: Hospitalization rate; CFR: Case fatality rate; * Control measures: A = isolation, B = report to competent authority, C = treatment, D = cleaning/disinfection, E = case finding/active
surveillance in crew, F = case finding/active surveillance in passengers or others, G = risk communication, H = contact tracing, I = crew vaccination, J = passenger vaccination, K = quarantine,
L = immunoglobulin (Ig) for crew, M = immunoglobulin (Ig) for passengers, N = other post-exposure prophylaxis (PEP) (describe details), O = disembarkation. ‡ Unkn. = unknown
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Table 2. Vaccine-preventable diseases identified through record review studies.
Disease
Dates (Number of
Affected Voyages,
Duration)
Diagnosis/Case Definition No. Cases (Crew,Passenger, Other)
Age (Years), Sex, Nationality of
Cases
Population at Risk/Crew
Attack Rate (of
Susceptible)
Place of
Occurrence/Ship Type
Control
Measures
Described *
Reference
Varicella
2005–2009 (unkn.,
5 years) Clinical varicella case 357 (278, 0, 79)
Crew: Median age 29 (range
20–66), 80% male
Three-quarters of crew cases were
from Caribbean countries,
Indonesia, the Philippines, or India
Most cases in spring and winter
2305 maritime illness
reports
Sailing in US
waters/passenger
A, B, C, E, F, G,
H, I, J [40]
November
2007–April 2008
(4 ships, 6 months)
Clinical varicella case 5 (5, 0, 0)
26–42 years, male
Majority from SE Asia and Eastern
European countries. Crew cases:
Indonesia (2), the Philippines (1),
Sri Lanka (2) Index: child
passenger on cruise (1) and crew
coming from home country during
incubation period (3)
13, 377, 28, and 882 crew,
respectively
Baltic
sea/Europe/Med/USA
and Caribbean/passenger
(2) cargo (1) work (feeder)
ship (1)
A, B, C, E, F, G,
H, I, J
(instructed but
unclear what
was carried out)
[39]
2009–2010, 34 ships
(2–25 days, 2 years) Clinical varicella case (probable case) 187 (151, 36, 0)
Unkn. >130 countries. 26
countries for crew cases with 58%
from 5 sub-tropical or tropical
countries (the Philippines,
Indonesia, India, Jamaica, St.
Vincent and the Grenadines)
694–6300 passengers per
ship;
400–2160 crew per ship.
Crew attack rate (of
susceptible)
For crew clusters reported:
(i) 29/860 (3.4%),
(ii) 10/2400 (0.4%)
World-wide/passenger A, B, C, E, F, G,H, I, J [38]
January
2010–December
2015, 99 outbreaks
Diagnosis of authority’s medical officer
967 (823 including
758 cruise ship crew,
144, 0)
Crew: 20–49: 394/399, 50+: 5/399,
Pax: <1: 3/99, 1–9: 46/99, 10–19:
18/99, 20–49: 24/99
50+: 8/99
Male 395/479 crew 60/106 pax
Female 84/479 crew 46/106 pax
Indonesia (21.7%, 80/369),
Philippines (17.6%, 65/369), or
India (17.3%, 64/369)
Unknown USA/63 cargo ships, 900cruise ships A, B, C, H, I, J, O [41]
Herpes zoster
January
2010–December
2015
Diagnosis of authority’s medical officer 13 (9 including 7cruise ship crew, 4, 0) Unkn. Unkn.
USA/2 cargo ships, 11
cruise ships Unkn. [41]
Mumps
January
2010–December
2014
Presumptive or final diagnoses based on the
information available from healthcare
facilities, health departments, medical
examiners, or laboratories, when available,
and review by a quarantine medical officer
35 (13, 22, 0) Unkn. Unkn. Unkn. Unkn. [11]
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Table 2. Cont.
Disease
Dates (Number of
Affected Voyages,
Duration)
Diagnosis/Case Definition No. Cases (Crew,Passenger, Other)
Age (Years), Sex, Nationality of
Cases
Population at Risk/Crew
Attack Rate (of
Susceptible)
Place of
Occurrence/Ship Type
Control
Measures
Described *
Reference
Meningitis/
meningococcal
disease
January
2010–December
2014
Presumptive or final diagnoses based on the
information available from healthcare
facilities, health departments, medical
examiners, or laboratories, when available,
and review by a quarantine medical officer
25 (9, 16, 0) Unkn. Unkn. Unkn. Unkn. [11]
Hepatitis A
January
2010–December
2014
Presumptive or final diagnoses based on the
information available from healthcare
facilities, health departments, medical
examiners, or laboratories, when available,
and review by a quarantine medical officer
22 (19, 3, 0) Unkn. Unkn. Unkn. Unkn. [11]
Measles
January
2010–December
2014
Any probable or confirmed measles case
determined to be contagious during travel.
Presumptive or final diagnoses based on the
information available from healthcare
facilities, health departments, medical
examiners, or laboratories, when available,
and review by a quarantine medical officer
21 (10, 11) Unkn. Unkn. Unkn. Unkn. [11]
Rubella
January
2010–December
2014
Presumptive or final diagnoses based on the
information available from healthcare
facilities, health departments, medical
examiners, or laboratories, when available,
and review by a quarantine medical officer
10 (4, 6) Unkn. Unkn. Unkn. Unkn. [11]
Pertussis
January
2010–December
2014
Presumptive or final diagnoses based on the
information available from healthcare
facilities, health departments, medical
examiners, or laboratories, when available,
and review by a quarantine medical officer
9 (0, 9) Unkn. Unkn. Unkn. Unkn. [11]
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Table 3. Seroprevalence studies.
Disease, Study
Duration [Reference]
Study Date
(Duration) Study Sample
Serological
Markers *
No. Study
Subjects (Age,
Sex, Nationality
Seropositivity SeropositivityBy Age
Seropositivity
by Nationality Susceptibility
Vaccination/Infection
History Risk Factors
Hepatitis Study/
1989–1991
[44]
1989–1991
(3 years)
US military
personnel
scheduled for
deployment on
11 US Navy ships
Anti-HAV+,
Anti-HBc+,
Anti-HBsAg+
Anti-HDV,
Anti-HCV+
2072 (male, mean
24 years; 72%
white)
Anti-HAV+
210 (10.1%);
Anti-HBc+
76 (3.7 %);
Anti-HCV+
9 (0.4%)
Increasing with
age: HAV+ 7.8%
in 18–24 years;
28.7% in >34
years
Anti-HBc+: 2.2%
in 18–24 yo; 7.2%
in 25–34 years;
8.3% in >34 years
For country of
birth:
Anti-HAV+ 8%
for USA and
39.3% for foreign;
HBV+ for 3.2%
USA, 10.7% for
foreign
HAV: 90%
28 subjects reported
a history of acute
hepatitis (50% were
anti HAV+
compared to 9.6%
without a history)
Anti-HAV positivity associated
with age, non-white racial/ethnic
group, born outside US and prior
Caribbean deployment for <1 year.
Anti-HBV with black and
Philippino race, foreign birth, a
history of STD and South
Pacific/Indian Ocean deployment
for <12 months, and S Pacific or
Med duty for >1 year
Hepatitis Study/1993
[43]
April–December
1993 (9 months)
Seamen
attending five
clinics
performing
mandatory
health
examinations of
seamen in
Denmark
Anti-HAV+,
Anti-HBc+,
Anti-HBsAg+,
Anti-HCV+
515 (86% male;
94%
Scandinavian)
Anti-HAV+
79 (15.3%);
Anti-HBc+
47 (9.1%);
Anti-HCV+
6 (1.2%)
Increasing with
age: HAV+ 0.3%
in <40; 71% in
60–69 years.
HBV+: 2.7% in
<40; 35.7% in >60
For origin:
Anti-HAV+
12.8% for
Scandinavian
and 52.4% for
foreign;
HBV+ 7.9% for
Scandinavian,
28.5% for foreign
HAV: 85%
1 HAV+ case
previously had HAV
vaccination
Anti-HAV and HBV positivity
associated with age. HAV
seroprevalence highest among
those who sailed in international
trade (outside USA and Europe)
Hepatitis Study/1998
[45]
February–July
1998
(6 months)
Personnel from a
Greek warship
Anti-HAV+,
Anti-HBsAg+
Anti-HBc+,
Anti-HBs+,
Anti-HCV+
263; (male, mean
age 24.4 years)
Anti-HAV+
0 (0%);
Anti-HBsAg+
3 (1.1 %);
Anti-HBc+,
4 (1.5%)
Anti-HBs+
45 (17.1%);
Anti-HCV+
1 (0.4%)
Unkn. Unkn. HAV: 100%
23 subjects reported
vaccination against
Hepatitis B (three
doses by 14 subjects)
Unkn.
Varicella Study/2008
[42]
1–23 December
2008 (3 weeks)
Cruise ship crew
members
undergoing
pre-employment
medical exam in
Mumbai and Goa
VZV IgM+ and
IgG +
121 (male, 21–42
years, 100%
Indian)
100 (82.7%) IgG+
0 (0%) IgM+ Unkn. Unkn.
16.5%
susceptibility
60% IgG pos. crew
could remember
disease or vaccine
history
Unkn.
* anti-HAV: antibodies to hepatitis A virus, anti-HBc: antibodies to hepatitis B core antigen, anti-HCV: antibodies to hepatitis C virus, Anti-HBsAg: antibodies to hepatitis B surface antigen,
VZV: Varicella Zoster Virus, IgM: immunoglobulin M, IgG: immunoglobulin G, Unkn.: unknown, STD: Sexually Transmitted Disease.
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Table 4. Characteristics of cases from reported outbreaks, case reports, and record reviews (results from seroprevalence studies not included).
Disease No. Clusters/
Outbreaks > 1 Cases
No. Crew Cases No. Pax Cases Total Crew,
Pax/Total Cases
n = 1795 (%)
No. Other
Cases
Male/Female Origin of Cases Ship Type
Out. Rep. ‡ Rev.Rec. ∞ Out. Rep. Rev. Rec
Measles 3 30 10 7 11 40, 18/58 (3, 2) 262 * 25/7
Asia, Europe, S. America,
Caribbean, Africa, Italy, India,
Philippines, Honduras,
Austria, Brazil,
Indonesia, unkn.
1 ferry, 2 cruise
Rubella 3 43 4 - 6 47, 6/53 (3, 0) 0 20/- German, unkn. 2 cruise, 1military
Hepatitis A 3 - 19 70 3 19, 73/92 (5, 1) 0 31/40 Polish, unkn. 4 river cruiseships
Meningococcal
meningitis 1 4 9 - 16 13, 16/ 29 (1, 6) 0 1/1 unkn.
2 cruise, 1
military
Mumps 1 9 13 - 22 22, 22/44 (2, 5) 0 -/- unkn. 1 military
Pertussis unkn
√
. - - - 9 0, 9/9 (0, 5) 0 -/- unkn. -
Herpes
zoster unkn. - 9 - 4 9, 4/13 (0, 7) 0 -/- unkn.
11 cruise, 2
cargo
Varicella 104 59 1257 1 180 1316, 181/1497(83, 4) 79
† 687/130
Indonesia, India, Philippines,
SE Asia, Eastern European
countries, Sri Lanka, Caribbean
countries, unkn.
909 cruise, 69
cargo
Total 115 145 1321 78 251 223, 1572/1795 341 764/179 1006
* For example, secondary cases on land, † either passenger cases or their contacts, ‡ Outbreak Report (Out.Rep.), ∞ Review Record (Rev.Rec.),
√
Unknown (unkn.).
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4. Discussion
The literature review showed that despite past and current evidence for VPDS cases and
outbreaks on ships, cross-border VPDs transmission and maritime occupational risks, documented
pre-employment examination of immune status, vaccination of seafarers, and travel advice to passenger
are not routinely conducted.
Most outbreaks and cases of VPDs identified were among crew members of cruise ships and
were varicella cases. Furthermore, the majority of outbreaks identified a crew member as the index
case and the origin of crew cases was from sub-tropical countries in many reports. Immune status of
crew members varies depending on the country of origin. Crew originating from countries with low
immunization rates and/or ongoing disease transmission could be index cases of outbreaks on board
ships [46]. Few data were identified in the literature about crew susceptibility. Seroprevalence studies
or surveys as part of outbreak response demonstrated approximately 13% to 16% susceptibility of
cruise ships’ crew to varicella [32,42], 11% to rubella [3,34], and high susceptibility of merchant seamen
to HAV (85%) [43]. VPDs such as varicella and measles can cause serious complications to adults and
an outbreak could affect the normal ship operation especially on ships with a small number of crew
sailing on long voyages [47]. In cruise ships, crew members could potentially expose large number of
passengers to pathogens depending on their duties and position such as staff in medical facilities and
beauty salons, waiters, bartenders, receptionists, and food handlers.
The International Medical Guide for Ships (IMGS) recommends immunization of susceptible
crew members after diagnosis of the first case of varicella on board a ship, as a measure to prevent
an outbreak, but not as a routine precautionary measure. In the US, varicella is the most frequent
VPDs reported on ships and one death of varicella pneumonia was reported in 2015 [11,25]. As a
regular pre-employment condition, IMGS requires immunization for diphtheria and tetanus for every
seagoing person, while for hepatitis A and hepatitis B for any crew member assigned to medical care
duties [47]. For all other crew, IMGS suggests immunization against hepatitis A and hepatitis B as
a “wise precaution”. Vaccinations for diseases including cholera, influenza, Japanese encephalitis,
meningococcal disease, poliomyelitis, rabies, typhoid fever, and yellow fever would depend on ship
destinations and type of freight carried according to IMGS [47]. According to the WHO (World Health
Organization) Handbook for Inspection of Ships and Issuance of Ship Sanitation Certificates, inspectors
when inspecting ships to issue Ship Sanitation Certificates should ensure that a list of crew members
taking care of children is available, indicating the vaccines they have received [48].The Maritime Labour
Convention (MLC) of the International Labour Organization (ILO) provides that competent authorities
adopt regulations to prevent diseases of seafarers on board [49]. Such regulations can include specific
vaccinations and assessment of immune status as a condition for employment of seafarers.
The literature review provided evidence for outbreaks of varicella, measles, rubella, mumps,
hepatitis A and meningococcal meningitis in crew. Cruise ships should gain adequate proof of immunity
from crew members and provide vaccination to those with inadequate proof, after considering
contraindications. In addition to the recommended vaccinations in the IMGS, we recommend
vaccination for measles, mumps, varicella, and rubella to be considered in the pre-employment policy
of seafarers, rather than as a response measure to prevent outbreaks after the first case occurred.
Outbreak control measures and medical evacuations at sea are very resource intensive [1,38,46], so
prevention policies involving vaccinations would be more cost effective than control.
The literature review revealed outbreaks of measles, rubella, herpes zoster, varicella, mumps,
hepatitis A, meningococcal meningitis, and pertussis among passengers of cruise ships. Passengers
need to be advised about vaccinations before travel, including for measles, mumps, varicella, and
rubella [31,34,40,42]. Especially travelers of at-risk groups should be vaccinated according to instructions
from family doctors and in sufficient time to develop immunity before boarding ships. Before travelling,
pregnant women should check for immunity for infectious disease and update immunizations as
needed [50]. Two authors, during investigations of rubella and varicella outbreaks, found pregnant
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crew members and passengers among the potentially exposed on board ships [1,34]. Vaccination of
crew can protect pregnant passengers and crew from exposure to VPDs that can affect pregnancy.
Global data on measles, which has been characterized as the most contagious disease, demonstrate
a significant increase in the last two years and this trend continues into the first quarter of 2019,
according to WHO [51]. Based on reports received by 30 EU/EEA Member States, ECDC has reported
that there is an ongoing large measles outbreak involving more than 44 thousand cases in the last
three years [52]. This global increase in measles outbreaks could affect maritime transport since index
cases are exposed ashore [3,22,31]. Outbreaks on ships can result in cross-border disease transmission,
as reported in two measles outbreaks where secondary cases occurred on land in 2014 [3,31,33].
Preparedness for response, as well as prevention strategies, are advised to be adopted by shipping
companies. In case of hospitalizations and laboratory diagnosis conducted ashore, communication
of public health information from ship doctors to port health authorities and health care services
on land and vice-versa are important to effectively and timely apply control measures [46]. The
European Commission new provisional edition of the document for a Regulation on the European
Maritime Single Window, suggest the establishment of a ship sanitation database for storing Maritime
Declaration of Health, which is expected to facilitate risk assessment and enhance communication
between port health authorities and ships [53].
The objectives of this review were achieved by collecting evidence mainly from published data. It
is possible that most cases and outbreaks are not published in the scientific literature. The majority
of cases were varicella cases collected by the US reporting system. Data collected in this review
are mainly from US and Europe. In Europe, even if there is an information system available to MS
to record cases and public health measures information, it is not systematically used in all EU MS.
Moreover, it is possible that cases or outbreaks have been reported to other non-EU countries, but those
were not considered in our study. It is unknown how many cases and outbreaks are not reported to
competent authorities.
The consortium of the EU SHIPSAN ACT joint action conducted the current literature review in
order to use its results to create a chapter for the prevention and control of VPDs in the European Manual
for Communicable Disease Surveillance and Hygiene Standards on Passenger Ships [16]. This manual
provides guidance to shipping companies and to port health authorities about pre-embarkation and
everyday preventive measures, as well as in response to cases and outbreaks. It suggests that seafarers
should maintain written proof of vaccination to demonstrate when needed during pre-employment
medical examinations and during voyages. Shipping companies should perform checks of immune
status when needed, conduct occupational risk assessments, administer vaccinations for varicella,
measles, and rubella in agreement with seafarers and keep up-to-date records of their staff [16].
Passengers should seek travel advice before cruising. Surveillance for early detection of VPD cases and
isolation of cases, contact tracing and reporting to competent authorities are also important measures.
Standard operating procedures should be available to port health authorities’ contingency plans on
how to respond to events of VPDs. Shipping companies’ prevention and control policies should also
include standard operating procedures about response measures to VPD events.
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